Stryker Corp stock (US8636671013): HR chief's recent share sales
Veröffentlicht: 13.05.2026 um 13:27 Uhr, Redaktion AD HOC NEWS, Redaktionelle Verantwortung: Rafael Müller (Chefredaktion)
Stryker Corp, a leading medical technology company, saw insider activity from its VP and Chief HR Officer M. Kathryn Fink. On May 8, 2026, she exercised 21,582 employee stock options at prices of $179.35 and $154.14 per share. The same day, 16,362 shares were withheld for taxes. On May 11, 2026, 3,500 shares were sold via trust at $283.45 average and 5,220 shares directly at $283.85 average, according to StockTitan as of May 13, 2026. This reflects routine post-exercise sales amid strong stock performance.
As of: 13.05.2026
By the editorial team – specialized in equity coverage.
At a glance
- Name: Stryker Corp.
- Sector/industry: Medical Devices
- Headquarters/country: United States
- Core markets: Orthopaedics, MedSurg, Neurotechnology
- Home exchange/listing venue: NYSE (SYK)
- Trading currency: USD
Stryker Corp: core business model
Stryker Corp develops and manufactures medical equipment, instruments, and software. The company operates in three main segments: Orthopaedics and Spine, MedSurg and Neurotechnology, and Stryker Spine. Products include joint replacement systems, surgical equipment, and endoscopic devices. Stryker serves hospitals and surgical facilities globally, with a strong US presence driving revenue.
Main revenue and product drivers for Stryker Corp
Orthopaedics contributes the largest share, fueled by hip and knee implants amid aging populations. MedSurg includes endoscopy and emergency care products. Neurotechnology covers cranial and spinal technologies. In Q1 2026 results published April 2026, organic net sales grew 9.1% year-over-year, per company filings. US market exposure remains key for investors tracking healthcare spending.
Official source
For first-hand information on Stryker Corp, visit the company’s official website.
Go to the official websiteRead more
Additional news and developments on the stock can be explored via the linked overview pages.
Why Stryker Corp matters for US investors
Stryker's NYSE listing and dominant role in US orthopaedics make it a staple for healthcare portfolios. The company benefits from Medicare reimbursement trends and elective procedure recovery post-pandemic. Shares traded around $283 USD on May 11, 2026, per insider filing data.
Conclusion
Stryker Corp continues to execute in medical devices with recent insider transactions highlighting liquidity events rather than signals of concern. The firm's US-centric revenue and innovation pipeline support its market position. Investors monitor upcoming earnings for growth updates.
Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
